The Biomanufacturing Excellence Act of 2025 mandates the establishment of a National Biopharmaceutical Center of Excellence under the National Institute of Standards and Technology (NIST). This Center will be created through a competitive grant or agreement with an eligible entity, such as a public-private partnership or institution of higher education. Its primary objectives are to advance the science of biopharmaceutical manufacturing, particularly for products critical to national, health, and economic security, and to reduce dependency on foreign supply chains. The Center will focus on developing and demonstrating flexible biopharmaceutical manufacturing technologies , improving upstream and downstream processes, and enhancing equipment and capabilities. It is also tasked with supporting good manufacturing practices , quality by design, and standardization to ensure efficient production and regulatory clarity for innovative methods. A crucial component of its mission involves advancing workforce training and development by collaborating with educational and community partners to bolster biotechnology talent. The bill authorizes $120,000,000 for fiscal year 2026 to fund the Center's operations, including facility construction, collaborative research, and workforce programs, and requires regular reports to Congress on its progress and findings.